Cannabis Injunction Lifted by Circuit Judge — Legal Analysis & Impact

Executive Summary

A circuit court judge has lifted a preliminary injunction that had blocked cannabis-related activities, marking a significant shift in the legal landscape for state-level marijuana programs. The decision removes judicial barriers that had prevented implementation of regulatory frameworks, licensing processes, or operational activities tied to cannabis commerce. While the specific jurisdiction and scope of the injunction remain tied to the underlying case details, the lifting represents a procedural victory for cannabis advocates and businesses that had been stalled by court intervention. The ruling allows previously halted activities to resume under existing state law, though appeals and further litigation remain possible. This development affects operators awaiting license approvals, patients seeking access to medical cannabis programs, and regulators tasked with implementing voter-approved or legislatively enacted cannabis frameworks.

The injunction's removal does not resolve the underlying legal dispute but permits activities to proceed while litigation continues. For cannabis businesses, this means potential resumption of application processes, facility inspections, product testing protocols, and retail operations that had been frozen. The decision carries implications for similar injunctions in other jurisdictions, as courts nationwide grapple with conflicts between state cannabis programs and federal prohibition under the Controlled Substances Act. Market participants now face the challenge of restarting operations that may have been suspended for months, requiring renewed capital deployment, workforce mobilization, and regulatory compliance efforts.

Why This Matters

The lifting of cannabis injunctions directly impacts thousands of license applicants, hundreds of thousands of patients, and billions in potential economic activity across affected jurisdictions. When courts issue preliminary injunctions against cannabis programs, they freeze entire regulatory ecosystems—halting license lotteries, preventing dispensary openings, blocking cultivation facility construction, and denying patient access to legal medicine. The economic stakes are substantial: a single state's adult-use program can generate $500 million to $2 billion in annual sales, supporting 10,000 to 30,000 jobs and producing $50 million to $300 million in tax revenue.

For medical cannabis patients, injunctions create access crises. Patients with qualifying conditions—including epilepsy, cancer, chronic pain, PTSD, and multiple sclerosis—lose legal pathways to obtain medicine when programs are enjoined. In states with limited dispensary networks, a single injunction can affect 50,000 to 200,000 registered patients. Pediatric epilepsy patients relying on high-CBD formulations face particular hardship, as injunctions often prevent new product approvals and facility expansions that would increase supply.

Cannabis operators face existential threats from injunctions. Multi-state operators (MSOs) commit $5 million to $20 million per market in pre-operational capital—real estate deposits, construction costs, equipment purchases, and staffing—before generating revenue. An injunction can strand these investments indefinitely, forcing companies to service debt without cash flow. Smaller operators lack the capital reserves to survive extended delays, leading to business failures, workforce layoffs, and market consolidation favoring well-capitalized MSOs.

The legal precedent matters beyond individual cases. Circuit court decisions on injunction standards influence how lower courts evaluate similar challenges nationwide. A ruling that lifts an injunction after finding insufficient evidence of irreparable harm or low likelihood of success on the merits strengthens the legal foundation for state cannabis programs. Conversely, rulings that maintain injunctions based on federal preemption arguments or Controlled Substances Act conflicts embolden opponents to file copycat lawsuits in other jurisdictions.

Background and History

Cannabis injunctions have been a recurring tool for opponents seeking to delay or derail state-level legalization efforts since the modern medical marijuana era began in 1996. Understanding the current injunction requires examining the broader history of judicial intervention in cannabis policy.

The California Precedent (1996-2005)

California's Proposition 215, passed in November 1996, established the nation's first comprehensive medical cannabis program. Within months, federal prosecutors sought injunctions against Oakland Cannabis Buyers' Cooperative and other dispensaries, arguing that state law could not authorize distribution of Schedule I controlled substances. In United States v. Oakland Cannabis Buyers' Cooperative (2001), the Supreme Court ruled 8-0 that federal law provided no medical necessity defense, effectively enjoining the cooperative's operations. This precedent established that federal enforcement could override state medical cannabis protections, though it did not invalidate state laws themselves.

The Department of Justice issued the Ogden Memorandum in October 2009, deprioritizing federal prosecution of individuals complying with state medical cannabis laws. This policy shift reduced federal injunction activity but did not eliminate state-level legal challenges. Local governments, property owners, and citizen groups increasingly sought state court injunctions to block dispensaries, cultivation facilities, and licensing programs.

Colorado and Washington Adult-Use Challenges (2012-2014)

When Colorado and Washington voters approved adult-use legalization in November 2012, opponents filed multiple lawsuits seeking to enjoin implementation. In Kramer v. Washington (2013), plaintiffs argued that Initiative 502 violated the Supremacy Clause by conflicting with the Controlled Substances Act. The Washington Supreme Court declined to issue an injunction, finding that state licensing and regulation did not require state officials to violate federal law—they merely declined to criminalize conduct under state law.

Nebraska and Oklahoma filed an original jurisdiction case at the U.S. Supreme Court in December 2014, seeking to enjoin Colorado's Amendment 64 implementation. The states argued that Colorado's legal cannabis market caused marijuana to flow across their borders, imposing enforcement costs. The Supreme Court declined to hear the case in March 2016, leaving Colorado's program intact and establishing that neighboring states lacked standing to challenge another state's cannabis laws.

Ohio Medical Program Injunction (2017-2018)

Ohio's medical cannabis program, authorized by House Bill 523 in June 2016, faced a preliminary injunction in Franklin County Common Pleas Court in October 2017. Plaintiffs challenged the State Medical Board of Ohio's rulemaking process, arguing that emergency rules violated the Administrative Procedure Act. Judge Mark Serrott issued a temporary restraining order halting license applications, delaying the program's launch by four months. The Tenth District Court of Appeals lifted the injunction in February 2018, finding that plaintiffs failed to demonstrate irreparable harm, as no licenses had yet been issued and the rulemaking process could be corrected without enjoining the entire program.

Illinois Social Equity Litigation (2020-2021)

Illinois launched adult-use sales on January 1, 2020, under the Cannabis Regulation and Tax Act. The state's social equity licensing provisions, designed to award licenses to applicants from communities disproportionately harmed by cannabis prohibition, faced immediate legal challenges. In Mays v. Raoul (2020), plaintiffs argued that the lottery system for awarding licenses violated due process and equal protection. Cook County Circuit Court Judge Moshe Jacobius issued a preliminary injunction in June 2020, halting the lottery for 75 dispensary licenses. The injunction remained in effect for 11 months, freezing $50 million in applicant investments and preventing 21,000 registered patients in underserved areas from accessing dispensaries. The Illinois Appellate Court lifted the injunction in May 2021, finding that the state's interest in implementing a legislatively approved program outweighed speculative harms to individual applicants.

New York Constitutional Challenge (2022-2023)

New York's Marijuana Regulation and Taxation Act, signed in March 2021, established a conditional adult-use licensing program prioritizing justice-involved individuals. In Variscal v. Hochul (2022), a Michigan-based operator challenged the residency requirements for Conditional Adult-Use Retail Dispensary (CAURD) licenses. U.S. District Judge Gary Sharpe issued a preliminary injunction in November 2022, finding that the residency requirement likely violated the dormant Commerce Clause. The injunction applied only to certain regions, creating a patchwork of halted and active licensing. The Second Circuit Court of Appeals partially stayed the injunction in March 2023, allowing some licenses to proceed while constitutional questions were litigated. The case settled in August 2023, with New York agreeing to modify residency requirements, demonstrating how injunctions can force policy changes even without final rulings on the merits.

Federal Rescheduling and Injunction Dynamics (2024-Present)

The Drug Enforcement Administration published a Notice of Proposed Rulemaking in May 2024 to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act. This administrative process, still ongoing as of July 2026, has influenced state-level injunction litigation. Plaintiffs opposing state programs increasingly argue that rescheduling uncertainty creates legal instability justifying injunctions. Conversely, defendants argue that federal movement toward rescheduling demonstrates evolving policy that undermines irreparable harm claims. Administrative Law Judge hearings on the rescheduling proposal began in December 2025, with a final rule expected in late 2026 or early 2027.

Key Players

Circuit Court Judges

Circuit court judges serve as intermediate appellate authorities in state judicial systems, reviewing trial court injunctions and setting precedent for lower courts. In cannabis cases, circuit judges evaluate whether trial courts properly applied the four-factor test for preliminary injunctions: likelihood of success on the merits, irreparable harm, balance of equities, and public interest. Their decisions carry significant weight, as they often represent the final practical resolution of injunction disputes—parties may appeal to state supreme courts, but those courts exercise discretionary review and accept only a fraction of cases. Circuit judges must balance competing interests: protecting constitutional rights, respecting legislative and voter intent, maintaining judicial restraint, and addressing practical consequences of their rulings.

State Attorneys General

State attorneys general defend cannabis programs against injunction challenges, representing regulatory agencies and state officials named as defendants. Their litigation strategies determine whether programs survive legal challenges. Attorneys general in states with robust cannabis programs—including California, Colorado, Illinois, and Massachusetts—have developed specialized cannabis litigation units. These teams defend licensing processes, rulemaking procedures, and statutory frameworks against constitutional challenges, administrative law claims, and federal preemption arguments. The quality of legal defense directly affects injunction outcomes: well-resourced offices with experienced cannabis litigators achieve higher success rates in defeating or quickly dissolving injunctions.

Cannabis Operators and Trade Associations

Multi-state operators including Curaleaf, Green Thumb Industries, Trulieve, Verano, and Cresco Labs have significant financial stakes in injunction litigation. These companies intervene as defendants in cases where injunctions threaten licenses they have been awarded or markets they have entered. Trade associations including the National Cannabis Industry Association, the U.S. Cannabis Council, and state-level groups coordinate amicus briefs, fund legal defense efforts, and provide expert testimony on industry standards and economic impacts. Smaller operators often lack resources to intervene individually but benefit from trade association advocacy.

Patient Advocacy Organizations

Organizations including Americans for Safe Access, the Epilepsy Foundation, and NORML represent patient interests in injunction litigation. These groups file amicus briefs documenting patient harms from program delays, provide testimony on medical necessity, and mobilize grassroots pressure on courts and policymakers. Patient advocates emphasize that injunctions deny medicine to vulnerable populations, including children with treatment-resistant epilepsy, cancer patients managing chemotherapy side effects, and veterans with PTSD. Their participation humanizes abstract legal disputes and provides courts with evidence of irreparable harm to third parties not directly involved in litigation.

Opposition Groups

Organizations including Smart Approaches to Marijuana (SAM), the Community Anti-Drug Coalitions of America, and local citizen groups file lawsuits seeking injunctions against cannabis programs. These plaintiffs argue that state programs violate federal law, endanger public health, and impose costs on communities. Their legal theories include Controlled Substances Act preemption, Administrative Procedure Act violations, constitutional challenges to licensing criteria, and zoning disputes. Opposition groups have achieved temporary injunctions in multiple jurisdictions, though most are eventually lifted or dissolved as cases proceed.

Legal and Regulatory Framework

Cannabis injunction litigation operates at the intersection of federal drug law, state constitutional provisions, administrative procedure statutes, and civil procedure rules governing preliminary relief. Understanding the legal framework requires examining multiple layers of authority.

Federal Controlled Substances Act

The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., classifies cannabis as a Schedule I controlled substance under 21 U.S.C. § 812(c). Schedule I designation indicates high abuse potential, no accepted medical use, and lack of accepted safety for use under medical supervision. Federal law prohibits manufacturing, distributing, dispensing, and possessing cannabis under 21 U.S.C. § 841(a)(1), with penalties ranging from civil fines to decades of imprisonment depending on quantity and prior offenses.

The Supremacy Clause, Article VI, Clause 2 of the U.S. Constitution, establishes that federal law preempts conflicting state law. However, courts have consistently held that state cannabis legalization does not violate the Supremacy Clause because states are not required to criminalize conduct that federal law prohibits—they may simply decline to enforce their own criminal penalties. This principle, established in cases including Kramer v. Washington and reaffirmed in subsequent litigation, means that state cannabis programs do not directly conflict with federal law in a manner requiring preemption.

State Administrative Procedure Acts

Every state has enacted an Administrative Procedure Act (APA) governing how agencies promulgate rules, issue licenses, and conduct adjudications. Cannabis injunction plaintiffs frequently allege APA violations, arguing that regulatory agencies exceeded statutory authority, failed to follow required rulemaking procedures, or applied licensing criteria arbitrarily. Common APA claims include: failure to provide adequate notice and comment periods for proposed rules; adoption of emergency rules without sufficient justification; inconsistent application of scoring criteria in competitive licensing processes; and failure to prepare required environmental or fiscal impact statements.

Courts evaluate APA claims under deferential standards of review. Agencies receive deference on questions of statutory interpretation under state-law equivalents of Chevron deference, and their factual findings are upheld if supported by substantial evidence. However, procedural violations—such as failing to publish proposed rules or conducting closed-door deliberations in violation of open meetings laws—can justify injunctions even when agencies acted within their substantive authority.

Preliminary Injunction Standards

Federal and state courts apply a four-factor test when evaluating preliminary injunction requests, as established in Winter v. Natural Resources Defense Council (2008) and adopted by most state courts. Plaintiffs must demonstrate: (1) likelihood of success on the merits of their underlying claim; (2) irreparable harm if the injunction is not granted; (3) the balance of equities tips in their favor; and (4) an injunction serves the public interest.

In cannabis cases, the likelihood of success factor requires courts to evaluate complex questions of federal preemption, state constitutional law, and administrative procedure. The irreparable harm factor often turns on whether plaintiffs can demonstrate concrete, imminent injury that cannot be remedied by money damages after a final judgment. Speculative harms—such as potential future competition from licensed dispensaries or generalized concerns about public safety—typically fail to meet the irreparable harm standard. The balance of equities and public interest factors require courts to weigh harms to plaintiffs against harms to defendants, intervenors, and the public. In cannabis cases, courts consider: economic harm to license applicants and operators; patient access to medicine; state interests in implementing voter-approved or legislatively enacted programs; and public safety concerns raised by opponents.

Tax Code Section 280E

Internal Revenue Code Section 280E prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses on federal tax returns. This provision, enacted in 1982 to prevent drug traffickers from claiming deductions, applies to state-legal cannabis businesses. Operators pay effective federal tax rates of 40% to 70%, compared to 15% to 30% for non-cannabis businesses, because they can deduct only cost of goods sold. Section 280E creates financial pressure that makes injunctions particularly harmful: operators must continue paying non-deductible rent, payroll, and compliance costs during injunction periods without generating revenue to offset these expenses. The proposed rescheduling of cannabis to Schedule III would eliminate 280E liability, providing significant tax relief, but this change has not yet been finalized.

State-by-State Breakdown

California

California operates the nation's largest cannabis market, with $5.3 billion in legal sales in 2025, but faces ongoing injunction litigation over local licensing disputes. The state's dual-licensing system requires operators to obtain both state licenses from the Department of Cannabis Control and local permits from cities or counties. Local governments retain authority to ban cannabis businesses entirely or limit the number of licenses through competitive processes. Injunction litigation in California typically involves challenges to local licensing ordinances, environmental review requirements under the California Environmental Quality Act (CEQA), and land use decisions. Los Angeles has faced multiple injunctions related to its social equity program, which prioritizes licenses for applicants from communities disproportionately impacted by cannabis prohibition. Possession limits: 28.5 grams of flower, 8 grams of concentrate for adults 21+; medical patients may possess amounts recommended by physicians.

Colorado

Colorado's mature regulatory framework, established in 2014, has faced fewer injunctions than newer programs, but local opt-out provisions create ongoing litigation. The state allows cities and counties to prohibit cannabis businesses through local ordinances or ballot measures. Injunction cases typically involve disputes over whether local bans were properly enacted or whether they conflict with state constitutional provisions in Amendment 64. The Colorado Court of Appeals has consistently upheld local authority to ban cannabis businesses, reducing the frequency of injunctions. Possession limits: 1 ounce of flower, 8 grams of concentrate for adults 21+; medical patients may possess 2 ounces of flower.

Illinois

Illinois has experienced significant injunction activity related to its social equity licensing program, as detailed in the Background section. The state awarded 185 conditional adult-use dispensary licenses in May 2021 after an 11-month injunction delay. Subsequent lottery rounds for craft grower and infuser licenses also faced injunction challenges, with plaintiffs alleging scoring irregularities and conflicts of interest in the application review process. The Illinois Department of Financial and Professional Regulation has revised its lottery procedures multiple times in response to litigation, implementing blockchain-based random selection and enhanced transparency measures. Possession limits: 30 grams of flower, 5 grams of concentrate for adults 21+; medical patients may possess 2.5 ounces of flower per 14-day period.

New York

New York's CAURD program faced the most significant injunction activity of any state program in 2022-2023, with federal court orders halting licensing in multiple regions. The state has since implemented a revised licensing structure, opening applications for general adult-use dispensary licenses alongside justice-involved prioritization. As of July 2026, New York has issued approximately 300 adult-use dispensary licenses, with 150 operational. The state continues to face litigation over licensing delays, with applicants seeking injunctions to compel the Office of Cannabis Management to process applications more quickly. Possession limits: 3 ounces of flower, 24 grams of concentrate for adults 21+; medical patients may possess 60-day supply as determined by practitioners.

Ohio

Ohio voters approved adult-use legalization through Issue 2 in November 2023, with sales beginning in August 2024. The state's Division of Cannabis Control has issued over 150 dual-use licenses to existing medical dispensaries, allowing them to serve both medical patients and adult-use customers. Ohio has experienced limited injunction activity compared to other states, partly because the legislature enacted implementing legislation that addressed many potential legal challenges preemptively. Local governments retain opt-out authority, and several municipalities have sought injunctions to enforce bans on cannabis businesses operating without local approval. Possession limits: 2.5 ounces of flower for adults 21+; medical patients may possess 90-day supply as determined by physicians.

Massachusetts

Massachusetts launched adult-use sales in November 2018 and has developed one of the most stable regulatory environments, with minimal injunction litigation. The state's Cannabis Control Commission has issued over 400 licenses across cultivation, manufacturing, testing, transportation, and retail categories. Injunction cases in Massachusetts typically involve local licensing disputes rather than challenges to the state regulatory framework. The commission's detailed regulations and robust administrative appeal process have reduced the frequency of court intervention. Possession limits: 1 ounce of flower in public, 10 ounces at home for adults 21+; medical patients may possess 10 ounces per 60-day period.

Market and Business Implications

The lifting of a cannabis injunction creates immediate market opportunities but also operational challenges for businesses that have been in suspended animation during litigation. Operators must rapidly mobilize capital, workforce, and supply chains while navigating regulatory requirements that may have evolved during the injunction period.

For multi-state operators, injunction resolution affects capital allocation decisions across their portfolios. MSOs typically budget $8 million to $15 million per dispensary, including real estate acquisition, construction, inventory, and pre-opening expenses. When an injunction halts operations, this capital is stranded—generating no return while debt service continues. The lifting of an injunction allows MSOs to activate these investments, but also requires additional capital to restart operations: rehiring staff who found other employment, refreshing inventory that may have expired, updating technology systems, and completing compliance requirements. Publicly traded MSOs including Curaleaf, Green Thumb Industries, and Trulieve disclose injunction-related delays in quarterly earnings reports, as these delays affect revenue projections and market expansion timelines.

Wholesale cannabis pricing responds quickly to injunction news. In markets where injunctions have limited the number of licensed dispensaries, wholesale prices for flower, concentrate, and manufactured products trade at premiums due to constrained retail access. When injunctions lift and new dispensaries open, wholesale prices typically decline 15% to 30% within 90 days as retail capacity increases and inventory moves more efficiently through the supply chain. Cultivators and manufacturers must adjust production volumes and pricing strategies to account for these market dynamics. Operators with excess inventory benefit from injunction resolution, as new retail outlets provide distribution channels. Conversely, operators who reduced cultivation during injunction periods face supply shortages and lost revenue opportunities as demand surges.

Real estate markets experience immediate impacts when injunctions lift. Cannabis-zoned properties—parcels that meet setback requirements from schools, parks, and residential areas—command significant premiums in limited-license markets. Property owners who leased to cannabis operators during injunction periods often renegotiate terms, seeking higher rents or equity participation now that operations can proceed. Landlords face their own challenges: many cannabis leases include force majeure clauses that excuse rent during regulatory delays, meaning landlords received reduced or no rent during injunction periods. The lifting of an injunction triggers rent resumption, but landlords may face tenants who lack capital to pay accumulated arrears.

Employment implications are substantial. A single dispensary employs 15 to 35 full-time equivalent workers, including budtenders, inventory managers, security personnel, and compliance staff. A cultivation facility employs 30 to 100 workers depending on canopy size. When injunctions halt operations, businesses furlough or terminate workers, who then find employment in other industries. Restarting operations requires recruiting and training new workforces, a process that takes 60 to 90 days and costs $150,000 to $400,000 in hiring, onboarding, and training expenses. States with mandatory cannabis worker training programs—including Massachusetts, Illinois, and California—require employees to complete certification courses before handling products, adding time and cost to restart timelines.

What Experts Say

Legal scholars and industry analysts emphasize that injunction litigation reflects broader tensions between state cannabis legalization and federal prohibition, with resolution requiring either federal rescheduling or explicit congressional authorization for state programs. According to Robert Mikos, a law professor at Vanderbilt University and cannabis federalism expert, state programs will continue to face legal challenges until Congress amends the Controlled Substances Act to create a safe harbor for state-compliant activities. Mikos has written extensively on how the anti-commandeering doctrine protects state legalization from federal preemption, but notes that this protection does not eliminate all legal vulnerabilities—particularly challenges based on state administrative law rather than federal preemption.

Industry analysts at cannabis research firms including BDSA, Headset, and Brightfield Group track injunction impacts on market forecasts. According to BDSA's 2026 market outlook, injunction-related delays have reduced total U.S. cannabis sales by an estimated $2.3 billion over the past three years, as programs in New York, Illinois, and other states experienced months-long or years-long implementation delays. These delays disproportionately benefit incumbent operators in medical-only markets, who face reduced competition from new adult-use entrants. BDSA projects that resolution of pending injunctions could add $800 million to $1.2 billion in annual sales across affected markets by 2027.

Patient advocates stress the human cost of injunctions. According to Matthew Schweich, deputy director of the Marijuana Policy Project, every month of delay in program implementation represents thousands of patients forced to choose between going without medicine or accessing illicit markets with unknown product quality and safety. Schweich points to data from states including Ohio and Pennsylvania showing that medical cannabis patient registration increases 20% to 40% in the first year after dispensary networks expand, suggesting that access barriers prevent many qualifying patients from enrolling in programs.

Cannabis attorneys who litigate injunction cases emphasize the importance of administrative law compliance in preventing challenges. According to Hilary Bricken, a cannabis attorney who has defended regulatory agencies in multiple injunction cases, agencies can minimize legal vulnerability by following transparent rulemaking processes, documenting decision-making rationales, and implementing robust conflict-of-interest policies for application reviewers. Bricken notes that many successful injunction challenges exploit procedural irregularities—such as ex parte communications between regulators and applicants, or scoring inconsistencies in competitive licensing—that could be avoided through rigorous administrative practices.

What's Next

The immediate aftermath of an injunction being lifted involves a 60 to 180-day restart period during which regulatory agencies reactivate licensing processes, operators complete compliance requirements, and markets adjust to new supply and demand dynamics. Specific next steps depend on the nature of the underlying case and the scope of activities that were enjoined.

If the injunction halted a licensing lottery or application review process, the regulatory agency must publish a revised timeline for completing the process. This typically involves: reopening application portals for a 30 to 60-day window to allow new applicants or permit existing applicants to update submissions; conducting application reviews using previously established scoring criteria; publishing preliminary results and allowing a 15 to 30-day protest period; resolving protests through administrative hearings; and issuing final license awards. The entire process typically takes 90 to 180 days from injunction lifting to license issuance.

If the injunction halted operations at already-licensed facilities, operators must complete reinspection and recertification processes. State regulatory agencies typically require: facility inspections to verify compliance with security, storage, and sanitation requirements; inventory audits to confirm that all products are properly tracked in seed-to-sale systems; staff background checks and training certifications; and updated insurance certificates and financial disclosures. Operators who maintained their facilities in ready-to-operate condition during the injunction can complete these requirements in 30 to 60 days. Operators who mothballed facilities or allowed licenses to lapse face longer timelines and potentially full re-application processes.

The underlying legal case continues even after an injunction is lifted. Preliminary injunctions are temporary measures pending final resolution of the merits. Plaintiffs may appeal the injunction lifting to higher courts, seeking to reinstate the injunction while appeals proceed. Defendants and intervenors may file motions for summary judgment, seeking to resolve the case without trial. If the case proceeds to trial, final judgment may not occur for 12 to 36 months after the injunction is lifted. During this period, the threat of a renewed injunction or an adverse final judgment creates ongoing uncertainty for market participants.

Federal rescheduling proceedings will influence future injunction litigation regardless of the outcome. If the DEA finalizes rescheduling to Schedule III, cannabis businesses will gain significant tax relief through elimination of 280E liability, but state programs will still conflict with federal law—Schedule III substances require DEA registration and FDA approval for medical use, neither of which state-licensed dispensaries possess. If rescheduling is rejected and cannabis remains Schedule I, opponents will continue to argue that state programs conflict with federal law. If cannabis is descheduled entirely—removed from the Controlled Substances Act—the primary legal basis for injunction challenges disappears, though other challenges based on state administrative law would remain possible.

Several key dates will shape the injunction landscape in the coming months. The DEA's final rule on rescheduling is expected between October 2026 and March 2027, following completion of Administrative Law Judge hearings and public comment review. Multiple state supreme courts have cannabis cases on their dockets for the 2026-2027 term, with decisions expected that will establish precedent on licensing procedures, local authority, and constitutional challenges. The U.S. Congress continues to consider federal cannabis legislation, including the SAFE Banking Act and various descheduling proposals, though passage remains uncertain given political divisions.

Further Reading

• Controlled Substances Act, 21 U.S.C. § 801 et seq. — https://www.govinfo.gov/content/pkg/USCODE-2021-title21/html/USCODE-2021-title21-chap13.htm
• Drug Enforcement Administration Notice of Proposed Rulemaking on Cannabis Rescheduling (May 2024) — https://www.federalregister.gov/cannabis-rescheduling
• United States v. Oakland Cannabis Buyers' Cooperative, 532 U.S. 483 (2001) — https://supreme.justia.com/cases/federal/us/532/483/
• Winter v. Natural Resources Defense Council, 555 U.S. 7 (2008) — https://supreme.justia.com/cases/federal/us/555/7/
• National Conference of State Legislatures Cannabis Overview — https://www.ncsl.org/health/cannabis-overview
• Marijuana Policy Project State Policy Database — https://www.mpp.org/states/
• NORML Legal Issues and Litigation — https://norml.org/laws/
• Americans for Safe Access Patient Resources — https://www.safeaccessnow.org/
• Congressional Research Service, "Marijuana: Medical and Retail—Selected Legal Issues" — https://crsreports.congress.gov